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Nonparathyroid Hypercalcemia
John T. Potts, Jr, MD^

f d. Note - This overview was originally presented at the
International Symposium on Clinical Disorders of Bone
and Mineral Metabolism, May 9-13,1983. The following
list indicates the presentations given in this session at the
Symposium and the contents ofthe corresponding
chapter in the Proceedings of the Symposium published by
Excerpta Medica. The numbers in parentheses refer to
pages in this volume. Complete information about the
contents ofthe Proceedings can be found at the back of
this issue.

The hypercalcemia of malignancy is important in differential diagnosis, since the physician must know whether a
given patient who presents with hypercalcemia has malignancy as the cause or a more benign disorder, such as
hyperparathyroidism or sarcoidosis. Hypercalcemia can
be life-threatening and must often be treated by general
measures even before the diagnosis is known. More definitive therapy, however, requires a firm diagnosis. Clinically, malignancy is often evident due to a variety of systemic symptoms and obvious signs and manifestations of
the tumor, but occasionally the presence of the malignancy is not obvious. There may be an occult tumor with a
slow clinical course, such as hypernephroma. Alternatively, in an individual with chronic obstructive pulmonary
disease, radiological detection of a lung tumor may be
difficult, and the symptoms of chronic disease difficult to
distinguish from the presence of malignancy.
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mation. Current theories of oncogenesis suggest that
overproduction of substances normally produced in
cells occurs as a " d o w n s t r e a m " effect of excessive action
of promotors or enhancers. In this regard, the association of hypercalcemia with certain types of tumor may
reveal interesting features of genetic translocation in
tumor cells responsible for hypercalcemia.
Clinical observations of tumor hypercalcemia have a
long and sometimes confusing history. In 1941, Albright
called attention to the peculiar "parathyroid-like" features of tumor hypercalcemia. Fifteen years later, Lafferty defined the syndrome of pseudohyperparathyroidism in his excellent 1966 review. A r o u n d 1972 Arnaud
and his colleagues f o u n d detectable or slightly elevated
immunoreactive PTH in most malignancies. However, a
year or two later, Powell and his colleagues in our group
f o u n d that immunoreactive PTH was not detectable in
blood o r t u m o r extracts in most patients with malignancy
and hypercalcemia. This confusing situation is still unresolved today. Parathyroid hormone is frequently detected
in the circulation of many patients, despite the growing

In many cases of hypercalcemia and malignancy, the
biologically responsible agent is not parathyroid hormone. Studies of the chemical and biological nature of
the tumor-derived factors responsible for the hypercalcemic syndrome(s) may provide clues to the physiological roles of the substances (assuming overproduction of
naturally occurring factors) and may contribute to the
knowledge of basic mechanisms of oncogenic transfor-
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evidence that the responsible tumor-derived agents are
not biologically identical to active parathyroid hormone
in the b l o o d . Hence, parathyroid hormone levels might
have been expected to be undetectable.
Several decades have elapsed since the initial clinical
interest in the etiology of the hypercalcemia of malign a n c y . O n l y r e c e n t l y have c e r t a i n c l i n i c a l tests
(1,25(OH)2D, fasting urinary calcium and bone biopsies)
begun to clarify the confusion surrounding this problem. Twenty years ago, Sherwood performed studies
with Aurbach, O'Riordan, and myself to indicate that
some tumors contained parathyroid hormone. Tashjian
and Munson had similar findings. Today, Singer, et al
(pp. 288 ff.) reviewed evidence about the frequency with
which immunoreactive PTH can be detected in tumor
extracts. Despite this evidence, many clinical and laboratory features noted in hypercalcemic patients with
cancer suggest that parathyroid hormone is not the
responsible mediator of the hypercalcemia. Hence,
attention has begun to focus on identification and isolation of tumor-derived agents distinct from parathyroid
hormone that act as bone resorbing factors.
Clinically, Stewart and Broadus and their colleagues
(pp. 284 ff.), as well as other groups, have made useful
advances in differential diagnosis by simultaneous application of hormonal assays and related biochemical techniques. Useful distinctions have been f o u n d between
patients with hypercalcemia of malignancy and those
with hypercalcemia due to hyperparathyroidism. Disagreements about certain findings among groups exist;
these must reflect variations in patient populations or
differences in techniques.
I n 1983, one can say with greater confidence that parathyroid hormone is not biologically responsible for tumor
hypercalcemia in most cases. The normal or even slightly
increased circulating immunoreactive PTH detected by

many laboratories may mean that inactive or incomplete
PTH is being secreted as a type of tumor marker. Alternatively, low levels of hormone may still be secreted by
suppressed glands at concentrations detectable by some
assays. Finally, abnormalities in blood proteins associated
with malignancy may affect immunoassay results in a
totally nonspecific fashion. Goltzman and colleagues
(pp. 6 ff.) indicated that this confusion aboutthe nature of
circulating "PTH-like" material in patients with malignancy is evident even in the cytochemical bioassay.
No clear consensus exists among groups about the practical usefulness of applying a battery of special assays,
such as nephrogenous cyclic DMP, 1,25(OH)D3, renal
tubular clearance of mineral ions, and other tests,
because of continuing disagreement about certain results
with these tests as used by different groups. Cost effectiveness of the approach is not clear. The best future
direction may derive f r o m present efforts to isolate and
chemically characterize the responsible nonparathyroid
tumor substances. Specificassaysfor these tumor factors
should be useful.
The evidence seems to point to multiple factors distinct
from one tumor to another. Different groups have identified tumor-derived growth factors, peptides of molecular weight several times larger than parathyroid
h o r m o n e , and peptides also distinct from parathyroid
hormone but similar in molecular size. Certain evidence
points to action of the factor through the parathyroid
hormone receptor with stimulation of cyclic AMP as
central to the mechanism ofaction o f t h e tumor-derived
hypercalcemic factors. However, others, as summarized
by Bringhurst and colleagues, (pp. 295 ff.) find bone
resorbing activity in the absence of increased cyclic AMP
production at the levels of the substance required to
resorb bone in in vitro assays. Hence, even in basic studies of tumor factors, a single direction of research f i n d ings is not yet evident.
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